Cover Image
市場調查報告書

MediPoint:生物可吸收支架 - 全球市場的分析與預測

MediPoint: Bioabsorbable Scaffolds - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 341945
出版日期 內容資訊 英文 251 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:生物可吸收支架 - 全球市場的分析與預測 MediPoint: Bioabsorbable Scaffolds - Global Analysis and Market Forecasts
出版日期: 2015年07月02日 內容資訊: 英文 251 Pages
簡介

冠狀動脈疾病 (CAD) 和週邊動脈疾病 (PAD) ,是關乎每年數百萬人的生命,全世界的公共衛生、社會問題。

本報告提供全球生物可吸收支架市場相關調查分析,以歐洲、印度、巴西、美國、中國、日本為焦點,提供疾病概要、競爭評估、未滿足需求、開發中產品驗證、主要企業簡介等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 冠狀動脈疾病
  • 週邊動脈疾病
  • 解剖、生理
  • 病理生理學
  • 臨床表現
  • 危險因素
  • 疾病市場區隔
  • 診斷
  • 臨床結果

第4章 競爭評估

  • 概要
  • Absorb BVS (Abbott Vascular)
  • Remedy (京都醫療設計)
  • DESolve (Elixir Medical Corperation)
  • Pure (Arterial Remodeling Technologies)

第5章 未滿足需求

  • 完全的生物可吸收支架的開發
  • 削減併發症的風險
  • 減少支架內支架治療的必要性
  • 長期臨床資料
  • 減少支架的破裂率
  • 雙重抗血小板療法
  • 成像

第6章 開發中產品

  • 概要
  • 冠狀動脈疾病:開發中產品
  • 週邊動脈疾病:開發中產品

第7章 產業概要

  • 治療趨勢

第8章 市場進入

  • 概要
  • 法規流程
  • 醫生的決策流程
  • 集團採購組織所扮演的角色
  • 臨床資料的不足
  • 地區層級的控制
  • 考慮成本
  • 償付趨勢
  • 法規問題/回收
  • 產品回收

第9章 M&A

  • ART、Terumo Corparation
  • Xenogenics Corporation、Multicell Technologies
  • Icon Interventional Systems、Ariad Pharmaceuticals
  • Boston Scientific Corporation

第10章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Abbott Vascular
    • 京都醫療設計
    • Arterial Remodeling Technologies
    • Elixir Medical Corporation
    • Cardionovum
    • Reva Medical
    • OrbusNeich Medical
    • Amaranth Medical
    • Biotronik
    • Lepu Medical Technology
    • HuaAn Biotechnology Co., Ltd.
    • Lifetech Scientific (Shenzhen) Co., LTD. (Lifetech Shenzhen)
    • Arterius
    • S3V Vascular Technologies
    • Tepha Inc.
    • Zorion Medical
    • Xenogenics Corporation
    • Meril Life Sciences
    • Boston Scientific Corporation
    • Icon Interventional Systems

第11章 推動市場要素、機會、障礙

  • 推動市場要素
  • 機會
  • 市場障礙

第12章 市場預測與預測

  • 全球市場概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 巴西
  • 中國
  • 印度

第13章 附錄

圖表

目錄
Product Code: GDME0214MAR

Coronary artery disease (CAD) and peripheral artery disease (PAD) are global public health and socioeconomic issues that affect millions of lives each year. Bioabsorbable scaffolds (BAS), which provide transient support to the vessel, are viable alternatives to permanent drug-eluting stents (DES) and bare metal stents (BMS) implants. In the report, BAS are defined as fully-bioabsorbable devices that are used in stenting procedures that completely disappear from the target vessel overtime. Stents such as BioMatrix Flex by Biosensors International and Synergy by Boston Scientific Corporation are not included in the report because they are metallic DES with bioabsorbable polymer coatings. Absorption of the bioabsorbable polymer coating still leaves behind a permanent BMS inside the vessel.

This report focuses on the BAS market in Europe (France, Germany, Italy, Spain, and the UK), India and Brazil, and the future markets of the US, China, and Japan. The global BAS markets are determined for the 10 countries covered in the report. This report identifies the unmet needs in the market, provides an understanding of physician perception of BAS, and evaluates the adoption of BAS in the future. Through GlobalData's analysis, it is evident that although there will be early adopters in Europe and eventually in the US, the widespread adoption of BAS will be slow. Large-scale, long-term studies need to be conducted to demonstrate their clinical efficacy, and new stent technologies need to be integrated appropriately into the existing reimbursement systems throughout Europe and the US. To successfully market BAS, companies need to design novel scaffold platforms that address the current unmet needs of conventional drug-eluting and BMS, and show superior clinical performance to the stents that are currently marketed and being used in modern clinics.

Highlights

Key Questions Answered

  • What is the current and future outlook of bioabsorbable scaffolds in developed and emerging markets?
  • What trends are affecting the global bioabsorbable scaffold market?
  • What are the market sizes of each bioabsorbable scaffold segment?
  • What are unmet needs in the bioabsorbable scaffold market? What are the clinical and non-clinical barriers in this space?
  • What is the physician perception and market outlook of bioabsorbable scaffolds, which are considered to be the fourth revolution in interventional cardiology?

Reasons to buy

  • "What Do Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Coronary Artery Disease
  • 3.2. Peripheral Artery Disease
  • 3.3. Anatomy and Physiology
  • 3.4. Pathophysiology
    • 3.4.1. Coronary Artery Disease
    • 3.4.2. Peripheral Artery Disease
  • 3.5. Clinical Presentation
    • 3.5.1. Symptoms of Coronary Artery Disease
    • 3.5.2. Symptoms of Peripheral Artery Disease
  • 3.6. Risk Factors
    • 3.6.1. Coronary Artery Disease
    • 3.6.2. Peripheral Artery Disease
  • 3.7. Disease Segments
    • 3.7.1. Coronary Artery Disease
    • 3.7.2. Peripheral Artery Disease
  • 3.8. Diagnosis
    • 3.8.1. Coronary Artery Disease
    • 3.8.2. Peripheral Artery Disease
  • 3.9. Clinical Outcomes
    • 3.9.1. Treatment Paradigm
    • 3.9.2. Treatment Modalities
    • 3.9.3. Coronary/Peripheral Artery Bypass Grafting
    • 3.9.4. Interventional Cardiology

4. Competitive Assessment

  • 4.1. Overview
  • 4.2. Absorb BVS - Abbott Vascular
    • 4.2.1. Efficacy
  • 4.3. Remedy - Kyoto Medical Planning
    • 4.3.1. Efficacy
  • 4.4. DESolve - Elixir Medical Corperation
    • 4.4.1. Efficacy
  • 4.5. Pure - Arterial Remodeling Technologies
    • 4.5.1. Efficacy

5. Unmet Needs

  • 5.1. Develop a Fully-Bioabsorbable Stent
  • 5.2. Reduce the Risk of Complications
  • 5.3. Reduce the Need for Stent-in-Stent Procedures
  • 5.4. Long-Term Clinical Data
  • 5.5. Reduce the Rate of Stent Fracture
  • 5.6. Dual Anti-Platelet Therapy
  • 5.7. Imaging

6. Pipeline Products

  • 6.1. Overview
  • 6.2. Coronary Artery Disease - Pipeline Products
    • 6.2.1. Overview
    • 6.2.2. Polymer-Based Bioabsorbable Scaffolds
    • 6.2.3. Metallic Bioabsorbable Scaffolds
    • 6.2.4. Summary
  • 6.3. Peripheral Artery Disease - Peripheral Bioabsorbable Scaffold Product Pipeline
    • 6.3.1. Overview
    • 6.3.2. Summary

7. Industry Overview

  • 7.1. Procedure Trends
    • 7.1.1. Global Coronary and Peripheral Stenting Procedure Trends
    • 7.1.2. Coronary Artery Disease
    • 7.1.3. Peripheral Artery Disease

8. Market Access

  • 8.1. Overview
  • 8.2. Regulatory Process
    • 8.2.1. United States
    • 8.2.2. 5EU
    • 8.2.3. Asia-Pacific
    • 8.2.4. Brazil
  • 8.3. Physician Decision-Making Process
  • 8.4. Role of Group Purchasing Organizations
  • 8.5. Lack of Clinical Data
  • 8.6. Regional-Level Control
  • 8.7. Cost Considerations
    • 8.7.1. United States
    • 8.7.2. 5EU
    • 8.7.3. Asia-Pacific
    • 8.7.4. Brazil
  • 8.8. Reimbursement Trends
    • 8.8.1. United States
    • 8.8.2. 5EU
    • 8.8.3. Asia-Pacific
    • 8.8.4. Brazil
  • 8.9. Regulatory Issues/Recalls
  • 8.10. Product Recalls

9. Mergers and Acquisitions

  • 9.1. ART and Terumo Corparation
  • 9.2. Xenogenics Corporation and Multicell Technologies
  • 9.3. Icon Interventional Systems and Ariad Pharmaceuticals
  • 9.4. Boston Scientific Corporation

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Abbott Vascular
    • 10.3.2. Kyoto Medical Planning Co., Ltd.
    • 10.3.3. Arterial Remodeling Technologies
    • 10.3.4. Elixir Medical Corporation
    • 10.3.5. Cardionovum
    • 10.3.6. Reva Medical
    • 10.3.7. OrbusNeich Medical
    • 10.3.8. Amaranth Medical
    • 10.3.9. Biotronik
    • 10.3.10. Lepu Medical Technology
    • 10.3.11. HuaAn Biotechnology Co., Ltd.
    • 10.3.12. Lifetech Scientific (Shenzhen) Co., LTD. (Lifetech Shenzhen)
    • 10.3.13. Arterius
    • 10.3.14. S3V Vascular Technologies
    • 10.3.15. Tepha Inc.
    • 10.3.16. Zorion Medical
    • 10.3.17. Xenogenics Corporation
    • 10.3.18. Meril Life Sciences
    • 10.3.19. Boston Scientific Corporation
    • 10.3.20. Icon Interventional Systems

11. Market Drivers, Opportunities and Barriers

  • 11.1. Market Drivers
    • 11.1.1. Rising Prevalence of Disease
    • 11.1.2. Avoid Stent-in-Stent Procedures
    • 11.1.3. Reduce/Eliminate Dual Anti-Platelet Therapy
    • 11.1.4. Availability of Long-Term Data
    • 11.1.5. Treatment Considerations
    • 11.1.6. Accurate Stent Placement
    • 11.1.7. Expected Launch of BAS in the US
  • 11.2. Opportunities
    • 11.2.1. BAS Segmentation
    • 11.2.2. Expanding the Indications for BAS
    • 11.2.3. Target High-Risk Patients
    • 11.2.4. Improve Deliverability of BAS
    • 11.2.5. Emerging Markets
  • 11.3. Market Barriers
    • 11.3.1. Slow Adoption
    • 11.3.2. Complications Associated with BAS
    • 11.3.3. High Average Selling Price
    • 11.3.4. Reimbursement
    • 11.3.5. Substitutes

12. Market Outlook and Forecast

  • 12.1. Global Market Overview
  • 12.2. United States
    • 12.2.1. Overview
    • 12.2.2. Market Analysis
  • 12.3. France
    • 12.3.1. Overview
    • 12.3.2. Market Analysis
  • 12.4. Germany
    • 12.4.1. Overview
    • 12.4.2. Market Analysis
  • 12.5. Italy
    • 12.5.1. Overview
    • 12.5.2. Market Analysis
  • 12.6. Spain
    • 12.6.1. Overview
    • 12.6.2. Market Analysis
  • 12.7. United Kingdom
    • 12.7.1. Overview
    • 12.7.2. Market Analysis
  • 12.8. Japan
    • 12.8.1. Overview
    • 12.8.2. Market Analysis
  • 12.9. Brazil
    • 12.9.1. Overview
    • 12.9.2. Market Analysis
  • 12.10. China
    • 12.10.1. Overview
    • 12.10.2. Market Analysis
  • 12.11. India
    • 12.11.1. Overview
    • 12.11.2. Market Analysis

13. Appendix

  • 13.1. Bibliography
  • 13.2. Abbreviations
  • 13.3. Report Methodology
    • 13.3.1. Overview
    • 13.3.2. Coverage
    • 13.3.3. Secondary Research
  • 13.4. Forecasting Methodology
  • 13.5. Physicians and Specialists Included in This Study
  • 13.6. About the Authors
    • 13.6.1. Analysts
    • 13.6.2. James Coutcher, Global Head of Healthcare
  • 13.7. About GlobalData
  • 13.8. Disclaimer

List of Tables

  • Table 1: Symptoms of CAD
  • Table 2: Symptoms of PAD
  • Table 3: Risk Factors Associated With CAD
  • Table 4: Risk Factors Associated With PAD
  • Table 5: Disease Segments for CAD
  • Table 6: Disease Segments for PAD
  • Table 7: Methods for Diagnosing CAD
  • Table 8: Methods for Diagnosing PAD
  • Table 9: Types of CABG
  • Table 10: Drugs Incorporated Into DES
  • Table 11: Marketed BAS Products
  • Table 12: Absorb BVS Product Profile
  • Table 13: Absorb BVS Clinical Trials
  • Table 14: Absorb BVS SWOT Analysis, 2015
  • Table 15: Remedy Product Profile
  • Table 16: Remedy SWOT Analysis, 2015
  • Table 17: DESolve Product Profile
  • Table 18: DESolve Clinical Trials
  • Table 19: DESolve SWOT Analysis, 2015
  • Table 20: Pure Product Profile
  • Table 21: Pure SWOT Analysis, 2015
  • Table 22: Coronary BAS Product Pipeline, 2015
  • Table 23: Igaki-Tamai Stent SWOT Analysis, 2015
  • Table 24: Fantom Scaffold SWOT Analysis, 2015
  • Table 25: ART18Z Scaffold SWOT Analysis, 2015
  • Table 26: Fortitude Scaffold SWOT Analysis, 2015
  • Table 27: ArterioSorb Scaffold SWOT Analysis, 2015
  • Table 28: ArterioSorb Scaffold SWOT Analysis, 2015
  • Table 29: Xinsorb Scaffold SWOT Analysis, 2015
  • Table 30: Ideal BioStent SWOT Analysis, 2015
  • Table 31: DREAMS Scaffold SWOT Analysis, 2015
  • Table 32: Peripheral BAS Product Pipeline, 2015
  • Table 33: Magic Explorer Scaffold SWOT Analysis, 2015
  • Table 34: ESPRIT BVS Stent SWOT Analysis, 2015
  • Table 35: GPOs in the US and EU
  • Table 36: Abbott Vascular Company Profile
  • Table 37: Marketed BAS Products by Abbott Vascular
  • Table 38: Pipeline BAS Products by Abbott Vascular
  • Table 39: Abbott Vascular SWOT Analysis, 2015
  • Table 40: Kyoto Medical PlanningCompany Profile
  • Table 41: Marketed BAS Products by Kyoto Medical Planning
  • Table 42: Pipeline BAS Products by Kyoto Medical Planning
  • Table 43: Kyoto Medical Planning SWOT Analysis, 2015
  • Table 44: ART Company Profile
  • Table 45: Marketed BAS Products by ART
  • Table 46: ART's BAS Pipeline Products
  • Table 47: ART SWOT Analysis, 2015
  • Table 48: Elixir Medical Corporation Company Profile
  • Table 49: Marketed BAS Products by Elixir Medical
  • Table 50: Elixir Medical Corporation SWOT Analysis, 2015
  • Table 51: Cardionovum Company Profile
  • Table 52: Cardionovum's BAS Pipeline Products
  • Table 53: Cardionovum SWOT Analysis, 2015
  • Table 54: REVA Medical's BAS Pipeline Products
  • Table 55: REVA Medical SWOT Analysis, 2015
  • Table 56: OrbusNeich Medical Company Profile
  • Table 57: OrbusNeich Medical's BAS Pipeline Products
  • Table 58: OrbusNeich Medical SWOT Analysis, 2015
  • Table 59: Amaranth Medical Company Profile
  • Table 60: Amaranth Medical's BAS Pipeline Products
  • Table 61: Amaranth Medical SWOT Analysis, 2014
  • Table 62: Biotronik Company Profile
  • Table 63: Biotronik's BAS Pipeline Products
  • Table 64: Biotronik SWOT Analysis, 2015
  • Table 65: Lepu Medical Technology Company Profile
  • Table 66: Lepu Medical Technology's BAS Pipeline Products
  • Table 67: Lepu Medical Technology SWOT Analysis, 2015
  • Table 68: HuaAn Biotechnology Co., Ltd. Company Profile
  • Table 69: HuaAn Biomedical Co., Ltd.'s BAS Pipeline Products
  • Table 70: HuaAn Biomedical Co., Ltd. SWOT Analysis, 2015
  • Table 71: Lifetech Scientific Co., LTD Company Profile
  • Table 72: Lifetech Scientific's BAS Pipeline Products
  • Table 73: Lifetech Scientific SWOT Analysis, 2015
  • Table 74: Arterius Company Profile
  • Table 75: Arterius BAS Pipeline Products
  • Table 76: Arterius SWOT Analysis, 2015
  • Table 77: S3V Vascular Technologies Company Profile
  • Table 78: S3V Vascular Technologies' BAS Pipeline Product
  • Table 79: S3V Vascular Technologies SWOT Analysis, 2015
  • Table 80: Tepha Inc.Company Profile
  • Table 81: Tepha Inc.'s BAS Pipeline Product
  • Table 82: Tepha Inc. SWOT Analysis, 2015
  • Table 83: Zorion MedicalCompany Profile
  • Table 84: Zorion Medical's BAS Pipeline Product
  • Table 85: Zorion Medical SWOT Analysis, 2015
  • Table 86: Xenogenics Corporation Company Profile
  • Table 87: Xenogenics Corporation's BAS Pipeline Product
  • Table 88: Xenogenics Corporation SWOT Analysis, 2015
  • Table 89: Meril Life Sciences Company Profile
  • Table 90: Meril Life Science's BAS Pipeline Product
  • Table 91: Meril Life Sciences SWOT Analysis, 2015
  • Table 92: Boston Scientific Corporation Company Profile
  • Table 93: Boston Scientific Corporation SWOT Analysis, 2015
  • Table 94: Icon Interventional Systems Company Profile
  • Table 95: Global BAS Market Revenue ($m), 2012-2021
  • Table 96: US BAS Market Revenue ($m), 2012-2021
  • Table 97: France BAS Market Revenue ($m), 2012-2021
  • Table 98: Germany BAS Market Revenue ($m), 2012-2021
  • Table 99: Italy BAS Market Revenue ($m), 2012-2021
  • Table 100: Spain BAS Market Revenue ($m), 2012-2021
  • Table 101: UK BAS Market Revenue ($m), 2012-2021
  • Table 102: Japan BAS Market Revenue ($m), 2012-2021
  • Table 103: Brazil BAS Market Revenue ($m), 2012-2021
  • Table 104: China BAS Market Revenue ($m), 2012-2021
  • Table 105: India BAS Market Revenue ($m), 2012-2021

List of Figures

  • Figure 1: Anatomy of the Human Heart
  • Figure 2: Pathophysiology of CAD
  • Figure 3: Pathophysiology of PAD
  • Figure 4: Treatment Modalities - CAD
  • Figure 5: Treatment Modalities - PAD
  • Figure 6: Types of Stents Used to Treat CAD and PAD
  • Figure 7: Global Coronary Artery Procedure Volume. By Stent Type, 2012-2021
  • Figure 8: Global Peripheral Artery Drug-Eluting and Bare-Metal Stenting Procedure Volume, By Artery Type, 2012-2021
  • Figure 9: Global Adoption Pattern of Stents Used to Treat CAD, 2021
  • Figure 10: Global Peripheral Bioabsorbable Scaffolding Procedure Volume, By Artery, 2012-2021
  • Figure 11: US Drug-Eluting and Bare Metal Stenting Procedure Volume, 2012-2021
  • Figure 12: 5EU Procedure Volume ofStents Used in Coronary Interventions, 2012-2021
  • Figure 13: APAC Procedure Volume of Stents Used in Coronary Interventions, 2012-2021
  • Figure 14: Brazil Procedure Volume of Stents Used in Coronary Interventions, 2012-2021
  • Figure 15: US Peripheral Stenting Procedure Volume, By Artery, 2012-2021
  • Figure 16: 5EU Peripheral Stenting Procedure Volume, by Artery, 2012-2021
  • Figure 17: Peripheral Drug-Eluting and Bare Metal Stent Usage, By Artery, 2014 and 2021
  • Figure 18: Peripheral BAS Use, By Artery, 2014 and 2021
  • Figure 19: APAC Peripheral Stenting Procedure Volume, by Artery, 2012-2021
  • Figure 20: Brazil Peripheral Stenting Procedure Volume, By Artery, 2012-2021
  • Figure 21: Global Coronary and Peripheral BAS Market Revenue ($m), 2012-2021
  • Figure 22: Global BAS Market Revenue, by Geography, 2014 and 2021
  • Figure 23: US BAS Market Revenue ($m), 2012-2021
  • Figure 24: France BAS Market Revenue ($m), 2012-2021
  • Figure 25: France Coronary and Peripheral BAS Market Revenue ($m), 2012-2021
  • Figure 26: Germany BAS Market Revenue ($m), 2012-2021
  • Figure 27: Germany Coronary and Peripheral BAS Market Revenue ($m), 2012-2021
  • Figure 28: Italy BAS Market Revenue ($m), 2012-2021
  • Figure 29: Italy Coronary and Peripheral BAS Market Revenue ($m), 2012-2021
  • Figure 30: Spain BAS Market Revenue ($m), 2012-2021
  • Figure 31: Spain Coronary and Peripheral BAS Market Revenue for Spain ($m), 2012-2021
  • Figure 32: UK BAS Market Revenue ($m), 2012-2021
  • Figure 33: UK Coronary and Peripheral BAS Market Revenue ($m), 2012-2021
  • Figure 34: Japan BAS Market Revenue ($m), 2012-2021
  • Figure 35: Brazil BAS Market Revenue ($m), 2012-2021
  • Figure 36: China BAS Market Revenue ($m), 2012-2021
  • Figure 37: India BAS Market Revenue ($m), 2012-2021
Back to Top